Английская Википедия:Fluticasone furoate/vilanterol
Шаблон:Short description Шаблон:Use dmy dates Шаблон:Drugbox
Fluticasone furoate/vilanterol, sold under the brand name Breo Ellipta among others, is a combination medication for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.[1] It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β2 agonist (ultra-LABA).[1]
In 2013, the drug was approved for use in the United States by the Food and Drug Administration (FDA) for long-term maintenance treatment of airflow obstruction in people with COPD, including chronic bronchitis and emphysema,[2] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma.[3] There were, however, concerns that LABAs such as vilanterol increase the risk of deaths due to asthma. In 2017, the FDA states that they were not justified.[2]
It is on the World Health Organization's List of Essential Medicines.[4] In 2021, it was the 108th most commonly prescribed medication in the United States, with more than 5Шаблон:Nbspmillion prescriptions.[5][6]
History
Approval
The combination was approved by the FDA for use as a long-term, once-daily, maintenance treatment in people with COPD in 2013. The FDA label was changed in April 2015, to add an indication for a once-daily treatment of asthma in people 18 years or older.[1] The exclusivity for a new product ended in May 2016, in the United States, and the exclusivity on the indication for asthma expired on 30 April 2018.[7] The patent for both indications expired on 3 August 2021.[7] The European Medicines Agency approved the drug for marketing on 13 November 2013.[8]
Society and culture
Commercial information
GlaxoSmithKline manufactures the combination. As of 31 December 2015, fluticasone furoate/vilanterol inhalation powder was approved for marketing in 73 countries, and had been launched in 45 countries.[9] Within the brand name, the Ellipta is the dry powder inhaler that the medication is administered in. Innoviva developed the active substance vilanterol, and receives royalties on sales.[10]
Research
There is tentative evidence as of 2016, that it is better than placebo for asthma.[11] Evidence is less strong in children.[11]
References
Шаблон:Drugs for obstructive airway diseases Шаблон:GlaxoSmithKline Шаблон:Portal bar
- ↑ 1,0 1,1 1,2 Ошибка цитирования Неверный тег
<ref>
; для сносокBreo Ellipta FDA label
не указан текст - ↑ 2,0 2,1 Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite book
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ 7,0 7,1 Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ 11,0 11,1 Шаблон:Cite journal
- Английская Википедия
- Drugs acting on the respiratory system
- Long-acting beta2-adrenergic agonists
- Combination COPD drugs
- Drugs developed by GSK plc
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
- Страницы с ошибками в примечаниях